# Apogee Therapeutics

Type: Company (APGE)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/apogee-therapeutics
Canonical HTML page: https://getbiobrief.com/entity/apogee-therapeutics

## Recent coverage (2 stories)

### How Rinvoq and Skyrizi Will Drive 21.5% EPS Growth at Q2 Print
2026-07-28 01:06:23 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

AbbVie's second-quarter results, expected to show $3.61 EPS, hinge on the continued clinical and commercial success of Rinvoq and Skyrizi. The Apogee deal underscores a deepening immunology pipeline as Humira fades into the rearview.
Full story: https://getbiobrief.com/story/abbvie-q2-2026-rinvoq-skyrizi-growth

### Analyst Sentiment Diverges for Biotech Leaders Apogee and Arcturus
2026-03-19 14:56:50 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Apogee Therapeutics and Arcturus Therapeutics experienced a wave of conflicting analyst activity on Thursday, with both companies facing significant downgrades alongside new initiations. This institutional tug-of-war highlights the increasing volatility and selective nature of investment in mid-cap biotechnology firms.
Full story: https://getbiobrief.com/story/apogee-arcturus-analyst-ratings-divergence

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.